Customized Solutions for Iron Metabolism-related Disease Drug Discovery & Development

Download

Iron metabolism-related disease, including both iron overload and iron deficiency diseases, poses significant challenges in therapy. Protheragen offers an all-in-one, integrated solution for developing innovative therapies targeting these conditions. We integrate biomarker discovery, target identification, disease modeling, and innovative diagnostic and therapeutic approaches to address the complex research needs associated with these conditions.

Furthermore, our expertise extends beyond therapeutic solutions, and we also offer a comprehensive suite of services for developing high-quality nutraceuticals and cosmetics that address health and beauty concerns related to iron metabolism.

Therapeutic Development Services

• Small Molecule Drug Development
• Gene Therapy Development
• Therapeutic Peptide Development
• Cell Therapy Development
• Therapeutic Antibody Development
• Therapeutic Protein Development

Disease Model Development Services

Case Study 01: Iron Overload-induced Osteoporosis Model Development

Rats were assigned to either the control group (which received saline injections) or the FAC group, which received injections of 100mg/kg of ferric ammonium citrate every three days. The FAC group’s iron overload-induced osteoporosis model was confirmed after two months. Micro-CT analysis revealed that bone mineral density (BMD) was significantly lower in the FAC group compared to the control group, confirming that iron overload had a negative impact on bone density. The H&E staining confirmed the FAC group had decreased trabecular bone in the femur and increased adipocytes in bone marrow.

Fig.1 FAC induced osteoporosis in SD rats.

Case Study 02: Animal Model Development for Iron Deficiency Anemia

An iron deficiency anemia (IDA) mouse model was created using a low-iron diet and blood draws every three days. Successfully modeled mice were thereafter randomly assigned to a model group and a therapy group (iron supplementation), while a group of normal mice served as the control. On day 26, the IDA model group demonstrated substantially lower levels of hemoglobin, RBC count, and serum iron, confirming model IDA. In therapy days 9 and 18, the therapy group showed no significant changes versus normal controls, demonstrating therapeutic efficacy.

Fig.2 IDA mouse model and evaluation of therapy effectiveness.

Protheragen focuses on developing bespoke solutions that align with each client's precise research requirements regarding iron metabolism as well as the intricate biological processes underlying the disease of interest. Reach out today regarding how our services can create tangible advancement in your research.